特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
960639

世界の PD-1 / PD-L1免疫療法市場:タイプ、用途、国のデータ(14か国)、および競合情勢状況-分析と予測、2019-2030に焦点を当てる

Global PD-1/PD-L1 Immunotherapy Market: Focus on Type, Application, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 255 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.41円
世界の PD-1 / PD-L1免疫療法市場:タイプ、用途、国のデータ(14か国)、および競合情勢状況-分析と予測、2019-2030に焦点を当てる
出版日: 2020年09月11日
発行: BIS Research Inc.
ページ情報: 英文 255 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のPD-1/PD-L1免疫療法の市場規模は予測期間中10.72%のCAGRで推移し、2030年には710億9790万米ドルの規模に成長すると予測されています。癌免疫療法は過去数年間で著しく進歩し、PD-1/PD-L1免疫療法はもっとも有力な治療法の1つとして浮上しています。多くの臨床試験でその重要性が証明されており、この治療法で治療できる他の癌を見つけるために多くの臨床試験が進行中です。

癌治療の分野におけるアンメットニーズ、癌の有病率の高さ、FDAによる迅速な承認の増加などの要因が同市場の成長を推進しています。一方で、薬剤開発と使用、償還関連のコストの高さが市場のさらなる成長を抑制しています。地域別で見ると、医療インフラの改善、一人当たりの所得の増加、即興型の償還政策により、北米地域が最大のシェアを保持しています。また、成長率では、アジア太平洋地域が期間中最大のCAGRを示すと予測されています。

当レポートでは、世界のPD-1/PD-L1免疫療法の市場を調査し、市場の定義と概要、COVID-19およびその他の市場影響因子の分析、価格・償還シナリオ、疫学、特許動向、法規制の枠組み、市場規模の推移・予測、タイプ・用途・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 技術の定義

第2章 市場範囲

第3章 調査手法

第4章 市場概要

  • PD-1/PD-L1免疫療法とその臨床的重要性
  • PD-1/PD-L1免疫療法の開発と商業化の情勢
  • 世界のPD-1/PD-L1免疫療法市場と成長の可能性
  • 価格・償還シナリオ
  • 特許の有効期限・バイオシミラーの市場参入の影響
  • COVID-19の影響

第5章 PD-1/PD-L1免疫療法の疫学

第6章 特許の情勢

第7章 市場力学

  • 概観
  • 影響分析
  • 促進要因
  • 抑制要因
  • 市場機会

第8章 産業考察

  • 概観
  • 規制シナリオ
  • 米国の法的要件と枠組み
  • 欧州の法的要件と枠組み
  • アジア太平洋の法的要件と枠組み

第9章 市場分析・予測:タイプ別

  • イントロダクション
  • PD-1阻害剤
    • 上市済み薬
    • パイプライン薬
  • PD-L1阻害剤
    • 上市済み薬
    • パイプライン薬

第10章 市場分析・予測:用途別

  • イントロダクション
  • 非小細胞肺癌(NSCLC)
  • 肝細胞癌(HCC)
  • 食道癌
  • 小細胞肺癌(SCLC)
  • 尿路上皮癌
  • その他

第11章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • その他の地域

第12章 競合情勢

  • 主な展開・戦略
  • 市場シェア分析

第13章 企業プロファイル

  • AstraZeneca Plc
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Eli Lilly & Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
目次
Product Code: BHL0947SA

Global PD-1/PD-L1 Immunotherapy Market to Reach $71,097.9 Million by 2030

Market Report Coverage - Global PD-1/PD-L1 Immunotherapy

Market Segmentation

  • Type: PD-1 and PD-L1 inhibitors
  • Application: Non-Small Cell Lung Cancer, Esophageal Cancer, Urothelial Carcinoma, Hepatocellular Carcinoma, Small Cell Lung Cancer, and Others

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, Rest-of-Europe
  • Asia-Pacific - Japan, China, India, Australia, South Korea, Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, Rest-of-Latin America
  • Rest-of-the-World

Growth Drivers

  • Rising Prevalence of Cancer
  • Unmet Medical Needs of Metastatic Cancer Patients
  • Advancements Made in the Field of Precision Medicine and Immuno-Oncology
  • Rising Awareness Among People for the Treatment of Cancer
  • Increasing Research and Development in the Field of Oncology
  • Increase in Disposable Income

Market Challenges

  • Adverse Effects of PD-1/PD-L1 Immunotherapy
  • Payment Policy and Reimbursement Issue
  • High Development Cost of New Therapy

Market Opportunities

  • Developing Healthcare Infrastructure in Emerging Economies

Key Companies Profiled

AstraZeneca Plc, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Plc, F. Hoffmann-La Roche Ltd., Novartis AG, Jiangsu HengRui Medicine Co. Ltd., Innovent Biologics, Inc., Sanofi S.A., Merck KGaA, Regeneron Pharmaceuticals Inc., BeiGene, Ltd., GlaxoSmithKline Plc, Eli Lilly & Company, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Key Questions Answered in this Report:

  • What are the various immune checkpoint inhibitors available in the market?
  • What are PD-1 and PD-L1 inhibitors, and what are their role and significance in the treatment of disease conditions?
  • What are the various therapeutics based on the PD-1 and PD-L1 inhibitors available in the market?
  • What are the current market size and future potential of these therapies?
  • What are the major market drivers, challenges, and opportunities in the global PD-1/PD-L1 immunotherapy market?
  • What are the various response prediction and influencing factors of PD-1 and PD-L1 blockade treatment?
  • What are the various combination therapy strategies followed with PD-1/PD-L1 immunotherapy?
  • What are the discovery timelines of various PD-1 and PD-L1 inhibitors?
  • What is the development status of biosimilars in this market? What will be the impact of its commercialization?
  • What is the patent landscape of this market? What will be the impact of patent expiry on this market?
  • What is the reimbursement scenario of the available therapeutics in this market?
  • What will be the impact of COVID-19 on this market?
  • What are the various PD-1/PD-L1 inhibitors in clinical trials/pipeline?
  • What is the mechanism of action of various cancer immunotherapeutic agents available in the market?
  • What are the guidelines implemented by different government bodies to regulate the approval of PD-1/PD-L1 immunotherapy?
  • What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R&D) investments?
  • Which are the leading players currently holding dominating shares in the global PD-1/PD-L1 immunotherapy market?
  • What are the key strategies incorporated by the players in the global PD-1/PD-L1 immunotherapy market, to sustain the competition?
  • What is the current revenue contribution of the global PD-1/PD-L1 immunotherapy market (by type), and how would it evolve in the forecast period, 2020-2030?
  • What is the current revenue contribution of different applications, and how would it evolve in the forecast period?
  • Which region is expected to contribute to the highest revenue of the global PD-1/PD-L1 immunotherapy market during the forecast period?

Market Overview

Cancer immunotherapy has significantly advanced in the past few years, and PD-1/PD-L1 immunotherapy has emerged out as one of the most prominent therapies. Many clinical trials have proved their significance, and many are still underway to find other cancers which can be treated with this therapy. These therapies have shown exceptional results in combination with other therapies with reasonable toxicity profile. Further, dynamic immunologic studies, along with genetics and epigenetics in the human cancer microenvironment, are expected to guide the development of different combination therapies and generate novel insight into how the human immune system responds to and is shaped by a variety of tumor types.

Our healthcare experts have found PD-1/PD-L1 immunotherapy to be one of the most rapidly adopted therapies, and the global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.

The unmet medical needs in the field of treatment of cancer is significantly driving the growth of this market. Other factors driving the growth include the high prevalence of cancer and increasing expedited approvals by FDA.

Despite the various factors that are influencing the growth of this market, there are several key issues that are needed to be addressed to facilitate future growth. The relatively high total costs of development and usage of PD-1/PD-L1 inhibitors and reimbursement policies are restraining the growth of this market.

Within the research report, the market is segmented on the basis of type, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the adoption of PD-1/PD-L1 immunotherapy at the global level has encouraged companies to invest in the development of products in the PD-1/PD-L1 immunotherapy segment for cancer treatment. Due to the diverse product portfolio and intense market penetration, Merck & Co., Inc. has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Technology Definition

  • 1.1 Inclusion and Exclusion Criteria
    • 1.1.1 Inclusions
    • 1.1.2 Exclusions

2 Market Scope

  • 2.1 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Criteria for Company Profiling

4 Market Overview

  • 4.1 PD-1/PD-L1 Immunotherapy and Their Clinical Importance
  • 4.2 PD-1/PD-L1 Immunotherapy Development and Commercialization Landscape
  • 4.3 Global PD-1/PD-L1 Immunotherapy Market and Growth Potential, 2019-2030
  • 4.4 Pricing and Reimbursement Scenario
  • 4.5 Impact of Patent Expiry and Entry of Biosimilars on Market
  • 4.6 Impact of COVID-19 on PD-1/PD-L1 Immunotherapy Market

5 Epidemiology of PD-1/PD-L1 Immunotherapy

6 Patent Landscape

7 Market Dynamics

  • 7.1 Overview
  • 7.2 Impact Analysis
  • 7.3 Drivers
    • 7.3.1 Rising Prevalence of Cancer
    • 7.3.2 Unmet Medical Needs of Metastatic Cancer Patients
    • 7.3.3 Advancements Made in the Field of Precision Medicine and Immuno-Oncology
    • 7.3.4 Rising Awareness Among People for the Treatment of Cancer
    • 7.3.5 Increasing Research and Development Expenditure in the Field of Oncology
    • 7.3.6 Increase in Disposable Income
  • 7.4 Restraints
    • 7.4.1 Adverse Effects of PD-1/PD-L1 Immunotherapy
    • 7.4.2 Payment Policy and Reimbursement Issue
    • 7.4.3 High Development Cost of New Therapy
  • 7.5 Opportunities
    • 7.5.1 Developing Healthcare Infrastructure in Emerging Economies

8 Industry Insights

  • 8.1 Overview
  • 8.2 Regulatory Scenario
  • 8.3 Legal Requirements and Frameworks in the U.S.
    • 8.3.1 Clinical Trial Authorization
    • 8.3.2 Marketing Authorization
    • 8.3.3 USFDA Guidelines for BLA Submission
    • 8.3.4 Post-Authorization Regulations
  • 8.4 Legal Requirements and Frameworks in Europe
    • 8.4.1 EMA Biologics License Application Process
    • 8.4.2 Centralized Procedure
    • 8.4.3 Decentralized Procedure
    • 8.4.4 Mutual-Recognition Procedure
    • 8.4.5 National Procedure
  • 8.5 Legal Requirements and Frameworks in Asia-Pacific
    • 8.5.1 China
    • 8.5.2 Japan
  • 8.6 Expedited Regulatory Designations Around the World

9 Global PD-1/PD-L1 Immunotherapy Market (by Type), $Million, 2019-2030

  • 9.1 Introduction
  • 9.2 PD-1 Inhibitors
    • 9.2.1 Commercialized Therapeutics
      • 9.2.1.1 Keytruda
      • 9.2.1.2 Opdivo
      • 9.2.1.3 Libtayo
    • 9.2.2 Pipeline Therapeutics
  • 9.3 PD-L1 Inhibitors
    • 9.3.1 Commercialized Therapeutics
      • 9.3.1.1 Tecentriq
      • 9.3.1.2 Imfinzi
      • 9.3.1.3 Bavencio
    • 9.3.2 Pipeline Therapeutics

10 Global PD-1/PD-L1 Immunotherapy Market (by Application), $Million, 2019-2030

  • 10.1 Introduction
  • 10.2 Non-Small Cell Lung Cancer (NSCLC)
  • 10.3 Hepatocellular Carcinoma (HCC)
  • 10.4 Esophageal Cancer
  • 10.5 Small Cell Lung Cancer (SCLC)
  • 10.6 Urothelial Carcinoma
  • 10.7 Others

11 Global PD-1/PD-L1 Immunotherapy Market (by Region), $Million, 2019-2030

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 U.K.
    • 11.3.3 France
    • 11.3.4 Italy
    • 11.3.5 Spain
    • 11.3.6 Rest-of-Europe
  • 11.4 Asia-Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 South Korea
    • 11.4.5 Australia
    • 11.4.6 Rest-of-APAC
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest-of-Latin America
  • 11.6 Rest-of-the-World

12 Competitive Landscape

  • 12.1 Key Developments and Strategies
    • 12.1.1 Regulatory and Legal Developments
    • 12.1.2 Partnerships, Alliances, and Business Expansions
    • 12.1.3 M&A Activities
    • 12.1.4 Funding Activities
  • 12.2 Market Share Analysis

13 Company Profiles

  • 13.1 Overview
  • 13.2 AstraZeneca Plc
    • 13.2.1 Company Overview
    • 13.2.2 Role of AstraZeneca Plc in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.2.3 Financials
    • 13.2.4 Key Insights About Financial Health of the Company
    • 13.2.5 SWOT Analysis
  • 13.3 BeiGene, Ltd.
    • 13.3.1 Company Overview
    • 13.3.2 Role of BeiGene, Ltd. in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.3.3 Financials
    • 13.3.4 Key Insights About Financial Health of the Company
    • 13.3.5 SWOT Analysis
  • 13.4 Bristol-Myers Squibb Company
    • 13.4.1 Company Overview
    • 13.4.2 Role of Bristol Myers Squibb Company in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.4.3 Financials
    • 13.4.4 Key Insights About Financial Health of the Company
    • 13.4.5 SWOT Analysis
  • 13.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
    • 13.5.1 Company Overview
    • 13.5.2 Role of Chia Tai Tianqing Pharmaceutical Group Co. Ltd. in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.5.3 Financials
    • 13.5.4 Key Insights About Financial Health of the Company
    • 13.5.5 SWOT Analysis
  • 13.6 Eli Lilly & Company
    • 13.6.1 Company Overview
    • 13.6.2 Role of Eli Lilly & Company in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.6.3 Financials
    • 13.6.4 SWOT Analysis
  • 13.7 F. Hoffmann-La Roche Ltd
    • 13.7.1 Company Overview
    • 13.7.2 Role of F. Hoffmann-La Roche Ltd. in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.7.3 Financials
    • 13.7.4 Key Insights About Financial Health of the Company
    • 13.7.5 SWOT Analysis
  • 13.8 GlaxoSmithKline plc
    • 13.8.1 Company Overview
    • 13.8.2 Role of GlaxoSmithKline plc in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.8.3 Financials
    • 13.8.4 Key Insights About Financial Health of the Company
    • 13.8.5 SWOT Analysis
  • 13.9 Innovent Biologics, Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Role of Innovent Biologics, Inc. in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.9.3 Financials
    • 13.9.4 Key Insights About Financial Health of the Company
    • 13.9.5 SWOT Analysis
  • 13.1 Jiangsu HengRui Medicine Co., Ltd.
    • 13.10.1 Company Overview
    • 13.10.2 Role of Jiangsu HengRui Medicine Co., Ltd. in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.10.3 Financials
    • 13.10.4 Key Insights About Financial Health of the Company
    • 13.10.5 SWOT Analysis
  • 13.11 Merck & Co., Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Role of Merck & Co., Inc. in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.11.3 Financials
    • 13.11.4 Key Insights About Financial Health of the Company
    • 13.11.5 SWOT Analysis
  • 13.12 Merck KGaA
    • 13.12.1 Company Overview
    • 13.12.2 Role of Merck KGaA in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.12.3 Financials
    • 13.12.4 Key Insights About Financial Health of the Company
    • 13.12.5 SWOT Analysis
  • 13.13 Novartis AG
    • 13.13.1 Company overview
    • 13.13.2 Role of Novartis AG in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.13.3 Financials
    • 13.13.4 Key Insights About Financial Health of the Company
    • 13.13.5 SWOT Analysis
  • 13.14 Pfizer Inc.
    • 13.14.1 Company Overview
    • 13.14.2 Role of Pfizer Inc. in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.14.3 Financials
    • 13.14.4 SWOT Analysis
  • 13.15 Regeneron Pharmaceuticals Inc.
    • 13.15.1 Company Overview
    • 13.15.2 Role of Regeneron Pharmaceuticals, Inc. in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.15.3 Financials
    • 13.15.4 Key Insights About Financial Health of the Company
    • 13.15.5 SWOT Analysis
  • 13.16 Sanofi S.A.
    • 13.16.1 Company Overview
    • 13.16.2 Role of Sanofi SA in the Global PD-1/PD-L1 Immunotherapy Market
    • 13.16.3 Financials
    • 13.16.4 Key Insights About Financial Health of the Company
    • 13.16.5 SWOT Analysis

List of Figures

  • Figure 1: NCI Fiscal Budget Year-on-Year, 2013-2018
  • Figure 2: Financial Burden of Cancer (2015)
  • Figure 3: Share of Prevalence of Cancer in Global Population
  • Figure 4: Number of People with Cancer (by Age) in Global Population
  • Figure 5: Global PD-1/PD-L1 Immunotherapy Market
  • Figure 6: Impact Analysis
  • Figure 7: Share of Key Developments and Strategies, June 2015-June 2020
  • Figure 8: Global PD-1/PD-L1 Inhibitors Market (by Type), 2019 and 2030
  • Figure 9: Global PD-1/PD-L1 Inhibitors Market (by Application), 2019 and 2030
  • Figure 10: Global PD-1/PD-L1 Inhibitors Market (by Region), 2019 and 2030
  • Figure 2.1: Global PD-1/PD-L1 Immunotherapy Market Segmentation
  • Figure 3.1: Global PD-1/PD-L1 Immunotherapy Market Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: PD-1/PD-L1 Clinical Trial Landscape
  • Figure 4.2: Global PD-1/PD-L1 Immunotherapy Market 2019-2030
  • Figure 4.3: Most Impacted Practices in the Treatment of Cancer
  • Figure 5.1: Prevalence of Melanoma Cancer in U.S. (Total Population)
  • Figure 5.2: Prevalence of Cervical Cancer in U.S. (Total Population)
  • Figure 5.3: Prevalence of Lung Cancer in U.S. (Total Population)
  • Figure 5.4: Prevalence of Renal Cell Carcinoma in U.S. (Total Population)
  • Figure 5.5: Prevalence of Squamous Cell Carcinoma of Head and Neck in U.S. (Total Population)
  • Figure 5.6: Target Population of Lung Cancer in U.S.
  • Figure 5.7: Target Population of Squamous Cell Carcinoma of Head and Neck in U.S.
  • Figure 5.8: Target Population of Renal Cell Carcinoma in U.S.
  • Figure 5.9: Target Population of Melanoma in U.S.
  • Figure 5.10: Target Population of Cervical Cancer in U.S.
  • Figure 6.1: Number of Patents Filed, January 2015-December 2019
  • Figure 6.2: Percentage of Patents Filed, By Patent Office, January 2015-December 2019
  • Figure 7.1: Number of People with Cancer (by Age) in Global Population
  • Figure 7.2: Household Disposable Income, US$/Capita
  • Figure 8.1: Steps for Obtaining Marketing Authorization
  • Figure 8.2: USFDA Review Timeline
  • Figure 8.3: EMA Review Timeline
  • Figure 9.1: Revenue Contribution of Different Segments, 2019 and 2030
  • Figure 9.2: Mechanism of Immunosuppression by PD-1/PD-L1 Axis
  • Figure 9.3: Global PD-1/PD-L1 Inhibitors Market (by PD-1 Inhibitors), 2019-2030
  • Figure 9.4: Global PD-1/PD-L1 Inhibitors Market (by PD-1 Inhibitors), 2019-2030
  • Figure 9.5: Global PD-1 Inhibitors Market (Keytruda), 2019-2030
  • Figure 9.6: Global PD-1 Inhibitors Market (Opdivo), 2019-2030
  • Figure 9.7: Global PD-1 Inhibitors Market (Libtayo), 2019-2030
  • Figure 9.8: Distribution of Drugs in Pipeline, by Phases
  • Figure 9.9: Global PD-1/PD-L1 Inhibitors Market (by PD-L1 Inhibitors), 2019-2030
  • Figure 9.10: Global PD-1/PD-L1 Inhibitors Market (by PD-L1 Inhibitors), 2019-2030
  • Figure 9.11: Global PD-L1 Inhibitors Market (Tecentriq), 2019-2030
  • Figure 9.12: Global PD-L1 Inhibitors Market (Imfinzi), 2019-2030
  • Figure 9.13: Global PD-L1 Inhibitors Market (Bavencio), 2019-2030
  • Figure 10.1: Revenue Contribution of Different Applications, 2019 and 2030
  • Figure 10.2: Global PD-1/PD-L1 Inhibitors Market (NSCLC), 2019-2030
  • Figure 10.3: Global PD-1/PD-L1 Inhibitors Market (HCC), 2019-2030
  • Figure 10.4: Global PD-1/PD-L1 Inhibitors Market (Esophageal Cancer), 2019-2030
  • Figure 10.5: Global PD-1/PD-L1 Inhibitors Market (Small Cell Lung Cancer), 2019-2030
  • Figure 10.6: Global PD-1/PD-L1 Inhibitors Market (Urothelial Carcinoma), 2019-2030
  • Figure 10.7: Global PD-1/PD-L1 Inhibitors Market (Others), 2019-2030
  • Figure 11.1: Global PD-1/PD-L1 Immunotherapy Market (by Region)
  • Figure 11.2 Global PD-1/PD-L1 Immunotherapy Market (by Region), 2019-2030
  • Figure 11.3: North America PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.4: North America: Market Dynamics
  • Figure 11.5: Revenue Contributions of Different Countries in North America, 2019 and 2030
  • Figure 11.6: U.S. PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.7: Canada PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.8: Europe PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.9: Europe: Market Dynamics
  • Figure 11.10: Revenue Contributions of Different Countries in Europe, 2019 and 2030
  • Figure 11.11: Germany PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.12: U.K. PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.13: France PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.14: Italy PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.15: Spain PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.16: Rest-of-Europe PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.17: Asia-Pacific PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.18: APAC: Market Dynamics
  • Figure 11.19: Revenue Contributions of Different Countries in Asia-Pacific, 2019 and 2030
  • Figure 11.20: China PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.21: Japan PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.22: India PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.23: South Korea PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.24: Australia PD-1/PD-L1 immunotherapy market, 2019-2030
  • Figure 11.25: RoAPAC PD-1/PD-L1 immunotherapy market, 2019-2030
  • Figure 11.26: Latin America PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.27: Latin America: Market Dynamics
  • Figure 11.28: Revenue Contributions of Different Countries in Latin America, 2019 and 2030
  • Figure 11.29: Brazil PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.30: Mexico PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.31: Rest-of-Latin America PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 11.32: RoW PD-1/PD-L1 Immunotherapy Market, 2019-2030
  • Figure 12.1: Share of Key Developments and Strategies, June 2015-June 2020
  • Figure 12.2: Regulatory and Legal Developments Share (by Company), June 2015-June 2020
  • Figure 12.3: Partnerships, Alliances, and Business Expansions (by Company), June 2015-June 2020
  • Figure 12.4: M&A Activities Share (by Company), June 2015-June 2020
  • Figure 12.5: Market Share Analysis (by Company), 2018 and 2019
  • Figure 13.1: Total Number of Companies Profiled
  • Figure 13.2: AstraZeneca Plc: Overall Product Portfolio
  • Figure 13.3: AstraZeneca plc: Overall Financials, 2017-2019
  • Figure 13.4: AstraZeneca plc: Revenue (by Segment), 2017-2019
  • Figure 13.5: AstraZeneca plc: Revenue (by Region), 2017-2019
  • Figure 13.6: AstraZeneca plc: R&D Expenditure, 2017-2019
  • Figure 13.7: AstraZeneca plc: SWOT Analysis
  • Figure 13.8: BeiGene, Ltd.: Overall Product Portfolio (Approved in China)
  • Figure 13.9: BeiGene, Ltd.: Overall Financials, 2017-2019
  • Figure 13.10: BeiGene, Ltd.: Revenue (by Region), 2017-2019
  • Figure 13.11: BeiGene, Ltd.: R&D Expenditure, 2017-2019
  • Figure 13.12: BeiGene, Ltd.: SWOT Analysis
  • Figure 13.13: Bristol Myers Squibb Company: Overall Product Portfolio
  • Figure 13.14: Bristol Myers Squibb Company: Overall Financials, 2017-2019
  • Figure 13.15: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
  • Figure 13.16: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
  • Figure 13.17: Bristol Myers Squibb Company: SWOT Analysis
  • Figure 13.18: Chia Tai Tianqing Pharmaceutical Group Co. Ltd.: Pipeline Product Portfolio
  • Figure 13.19: Chia Tai Tianqing Pharmaceutical Group Co. Ltd.: Overall Financials, 2018-2019
  • Figure 13.20: Chia Tai Tianqing Pharmaceutical Group Co. Ltd.: R&D Expenditure, 2017-2019
  • Figure 13.21: Chia Tai Tianqing Pharmaceutical Group Co. Ltd.: SWOT Analysis
  • Figure 13.22: Eli Lilly & Company: Product Portfolio (China)
  • Figure 13.23: Eli Lilly & Company: Overall Financials, 2017-2019
  • Figure 13.24: Eli Lilly & Company: Revenue (by Region), 2017-2019
  • Figure 13.25: Key Insights About Financial Health of the Company
  • Figure 13.26: Eli Lilly & Company: SWOT Analysis
  • Figure 13.27: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 13.28: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 13.29: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 13.30: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 13.31: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 13.32: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 13.33: GlaxoSmithKline plc: Pipeline Product Portfolio
  • Figure 13.34: GlaxoSmithKline plc: Overall Financials, 2017-2019
  • Figure 13.35: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
  • Figure 13.36: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
  • Figure 13.37: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
  • Figure 13.38: GlaxoSmithKline plc: SWOT Analysis
  • Figure 13.39: Innovent Biologics, Inc.: Product Portfolio (China)
  • Figure 13.40: Innovent Biologics, Inc.: Overall Financials, 2018-2019
  • Figure 13.41: Innovent Biologics, Inc.: R&D Expenditure, 2017-2019
  • Figure 13.42: Innovent Biologics, Inc.: SWOT Analysis
  • Figure 13.43: Jiangsu HengRui Medicine Co., Ltd.: Pipeline Product Portfolio
  • Figure 13.44: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, 2018-2019
  • Figure 13.45: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, 2017-2019
  • Figure 13.46: Jiangsu HengRui Medicine Co., Ltd.: SWOT Analysis
  • Figure 13.47: Merck & Co., Inc.: Product Portfolio
  • Figure 13.48: Merck & Co., Inc.: Overall Financials, 2017-2019
  • Figure 13.49: Merck & Co., Inc.: Revenue (by Segment), 2017-2019
  • Figure 13.50: Merck & Co., Inc.: Revenue (by Region), 2017-2019
  • Figure 13.51: Merck & Co., Inc.: R&D Expenditure, 2017-2019
  • Figure 13.52: Merck & Co., Inc.: SWOT Analysis
  • Figure 13.53: Merck KGaA: Product Portfolio
  • Figure 13.54: Merck KGaA: Overall Financials, 2017-2019
  • Figure 13.55: Merck KGaA: Revenue (by Segment), 2017-2019
  • Figure 13.56: Merck KGaA: Revenue (by Region), 2017-2019
  • Figure 13.57: Merck KGaA: R&D Expenditure, 2017-2019
  • Figure 13.58: Merck KGaA: SWOT Analysis
  • Figure 13.59: Novartis AG: Overall Financials, 2017-2019
  • Figure 13.60: Novartis AG Net Revenue (by Business Segment), 2017-2019
  • Figure 13.61: Novartis AG: Net Revenue (by Region), 2017-2019
  • Figure 13.62: Novartis AG: R& D Expense, 2017-2019
  • Figure 13.63: Novartis AG: SWOT Analysis
  • Figure 13.64: Pfizer Inc.: Overall Product Portfolio
  • Figure 13.65: Pfizer Inc.: Overall Financials, 2017-2019
  • Figure 13.66: Pfizer Inc.: Revenue (by Segment), 2017-2019
  • Figure 13.67: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
  • Figure 13.68: Pfizer Inc.: Revenue (by Region), 2017-2019
  • Figure 13.69: Pfizer Inc: R&D Expenditure, 2017-2019
  • Figure 13.70: Pfizer Inc.: SWOT Analysis
  • Figure 13.71: Regeneron Pharmaceuticals, Inc.: Overall Product Portfolio
  • Figure 13.72: Regeneron Pharmaceuticals, Inc.: Overall Financials, 2017-2019
  • Figure 13.73: Regeneron Pharmaceuticals, Inc.: R&D Expenditure, 2017-2019
  • Figure 13.74: Regeneron Pharmaceuticals, Inc.: SWOT Analysis
  • Figure 13.75: Sanofi SA: Overall Product Portfolio
  • Figure 13.76: Sanofi SA: Overall Financials, 2017-2019
  • Figure 13.77: Sanofi SA: Revenue (by Segment), 2017-2019
  • Figure 13.78: Sanofi SA: Revenue (by Region), 2017-2019
  • Figure 13.79: Sanofi SA: R&D Expenditure, 2017-2019
  • Figure 13.80: Sanofi SA: SWOT Analysis

List of Tables

  • Table 1: Leading Players in Global PD-1/PD-L1 Immunotherapy Market
  • Table 4.1: Clinical Studies About Pembrolizumab
  • Table 4.2: Clinical Studies About Nivolumab
  • Table 4.3: Commercialized PD-1/PD-L1 Products
  • Table 5.1: Type of Tumors Treated by PD-1/PD-L1 Immunotherapy
  • Table 6.1: Share of Patents Filed, January 2015-December 2019
  • Table 7.1: Impact Analysis
  • Table 7.2: Comparison of R&D Expenditure by Major Pharmaceutical Companies, 2018 and 2019
  • Table 7.3: Most Common Side Effects to PD-1/PD-L1 Immunotherapy
  • Table 8.1: Regulatory Scenario Across the World
  • Table 8.2: Expedited Regulatory Designations Around the World
  • Table 9.1: Keytruda Indications, Usage, and Dose
  • Table 9.2: Opdivo Indications, Usage, and Dose
  • Table 9.3: Libtayo Indications, Usage, and Dose
  • Table 9.4: Phase 2 - Pipeline PD-1 inhibitors
  • Table 9.5: Phase 3 - Pipeline PD-1 inhibitors
  • Table 9.6: Tecentriq Indications, Usage, and Dose
  • Table 9.7: Imfinzi Indications, Usage, and Dose
  • Table 9.8: Bavencio Indications, Usage, and Dose
  • Table 9.9: Phase 2 - Pipeline PD-1 inhibitors
  • Table 9.10: Phase 3 - Pipeline PD-1 inhibitors
  • Table 10.1: First Line Treatment Options, If Marker is Present: PD-L1 ≥1%
  • Table 10.2: First Line Treatment for Adenocarcinomas, Large Cell and Unknown Types, if Marker is Absent or Unknown
  • Table 10.3: Next-in-Line Treatment for Adenocarcinomas, Large Cell and Unknown Types, if Marker is Absent or Unknown
  • Table 10.4: First Line Treatment for Squamous Cell Carcinoma if Marker is Absent or Unknown
  • Table 10.5: Next-in-Line Treatment for Squamous Cell Carcinoma if Marker is Absent or Unknown
  • Table 10.6: PD-1/PD-L1 Inhibitors for the Treatment of HCC
  • Table 10.7: PD-1/PD-L1 Inhibitors for the Treatment of Esophageal Cancer
  • Table 10.8: PD-1/PD-L1 Inhibitors for the Treatment of Small Cell Lung Cancer
  • Table 10.9: PD-1/PD-L1 Inhibitors for the Treatment of Urothelial Carcinoma
  • Table 13.1: AstraZeneca Plc: Pipeline Product Portfolio
  • Table 13.2: BeiGene, Ltd.: Pipeline Product Portfolio
  • Table 13.3: Bristol Myers Squibb Company: Pipeline Product Portfolio
  • Table 13.4: Eli Lilly & Company: Pipeline Product Portfolio
  • Table 13.5: F. Hoffmann-La Roche Ltd.: Pipeline Product Portfolio
  • Table 13.6: Innovent Biologics, Inc.: Pipeline Product Portfolio
  • Table 13.7: Merck & Co., Inc.: Pipeline Product Portfolio
  • Table 13.8: Merck KGaA: Pipeline Product Portfolio
  • Table 13.9: Novartis AG: Pipeline Product Portfolio
  • Table 13.10: Pfizer Plc: Pipeline Product Portfolio
  • Table 13.11: Regeneron Pharmaceuticals, Inc.: Pipeline Product Portfolio
  • Table 13.12: Sanofi SA: Pipeline Product Portfolio
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.